Panacea Biotec share price
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Last close ₹311.45down ₹15.35 (4.70%)BSE ₹311.40
Share price at the NSE close on 23 Oct 2026. Previous close ₹326.80.
52-week range of traded prices to 23 Oct 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,908 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 31 May 2026
- 2.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 31 May 2026
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 82,88547.4% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹200 Crup 19.68%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹2.20 CrQuarter to Mar 2026: −₹1.00 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 1.1%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 8 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, part of the business was demerged on 21 Sep 2020, and figures before the change include the part that left.
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 31 May | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Net profit | 5 | 4 | −2 | 4 | −14 | 4 | −1 | 2 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 3.2% | 2.7% | −1.5% | 2.4% | −9.9% | 2.4% | −0.6% | 1.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- VaccinesVaccines, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹410 Crup 32.41%64.1%
- FormulationsFormulations, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹230 Crdown 7.92%35.9%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 54% of 1,084 trading days over the last 5 years.
LowestHighest
Its median1.4Industry median2.9
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −32.9% | – | – | 0.0% |
| 3 years | +39.8% | – | – | 0.0% |
| 5 years | +10.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 461 | 0.04% | ₹0.02 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 217 | 0.04% | ₹79,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Panacea Biotec in market cap.
Panacea Biotec is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Indoco RemediesINDOCO | 2,091 | 371.3 | 2.2 | 18.7 | +12.1% | – | 0.6% | 1.7% | 0.09% |
 Sai ParenteralsSAIPARENT | 2,040 | – | 4.2 | – | – | – | – | – | 0.00% |
 Syncom Formulations (India)SYNCOMF | 1,992 | 23.3 | 4.8 | 22.6 | +0.4% | +48.6% | 22.6% | 19.5% | 0.47% |
 Sakar HealthcareSAKAR | 1,980 | 46.2 | 5.7 | 22.4 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Venus RemediesVENUSREM | 1,877 | 16.2 | 2.8 | 11.1 | +19.9% | +116.3% | 19.0% | 21.1% | 0.71% |
 Windlas BiotechWINDLAS | 1,801 | 27.1 | 3.1 | 17.4 | +18.5% | +2.4% | 12.2% | 12.2% | 0.72% |
 Hester BiosciencesHESTERBIO | 1,750 | 12.8 | 4.9 | 22.3 | +4.1% | +262.2% | 40.4% | 11.7% | 0.53% |
 NGL Fine-ChemNGLFINE | 1,634 | 28.6 | 5.0 | 20.6 | +40.5% | – | 18.7% | 14.5% | 0.07% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
| Ex-date | Type | Per share |
|---|---|---|
| 19 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.75 |
| 16 Sep 2010 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.25 |
| 19 Sep 2008 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | 100% of face value (₹1.00 a share) |
| 21 Sep 2007 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | 100% of face value (₹1.00 a share) |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Panacea Biotec share price by year
Each calendar year to 2025.Panacea Biotec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 376.30 | −10.1% | 566.20 | 297.25 |
| 2024 | 418.60 | +149.3% | 484.90 | 119.05 |
| 2023 | 167.90 | +18.2% | 177.65 | 107.55 |
| 2022 | 142.05 | −28.5% | 264.95 | 125.75 |
| 2021 | 198.65 | −17.1% | 439.25 | 172.20 |
| 2020Demerger | 239.55 | +82.4% | 245.45 | 97.15 |
| 2019 | 131.30 | −18.0% | 206.65 | 111.10 |
| 2018 | 160.15 | −34.1% | 350.90 | 144.65 |
| 2017 | 243.00 | +106.8% | 288.35 | 118.70 |
| 2016 | 117.50 | −12.4% | 141.05 | 85.35 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 21 Sep 2020 reinvested, the change in 2020 is +98.9%.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 328.05 | 328.05 | 304.80 | 311.45 | 312.66 | 82,885 | 47.4% |
| 22 Oct 2026 | 335.00 | 338.35 | 326.00 | 326.80 | 331.07 | 40,228 | 55.5% |
| 21 Oct 2026 | 349.00 | 350.35 | 336.10 | 339.50 | 341.79 | 61,807 | 50.4% |
| 19 Oct 2026 | 357.70 | 357.70 | 342.95 | 349.05 | 349.59 | 69,574 | 57.7% |
| 16 Oct 2026 | 356.60 | 363.45 | 351.00 | 359.70 | 358.78 | 25,780 | 52.5% |
| 15 Oct 2026 | 362.85 | 363.00 | 354.00 | 357.00 | 357.34 | 32,719 | 57.8% |
| 14 Oct 2026 | 349.55 | 366.00 | 348.80 | 360.50 | 358.72 | 94,832 | 54.9% |
| 13 Oct 2026 | 345.40 | 350.90 | 335.00 | 349.55 | 343.01 | 81,804 | 41.3% |
| 12 Oct 2026 | 346.00 | 351.50 | 344.95 | 346.95 | 348.45 | 34,179 | 55.4% |
| 9 Oct 2026 | 345.05 | 350.90 | 338.25 | 345.25 | 345.92 | 58,030 | 40.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Buyback and demerger history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 21 Sep 2020 | Demerger | 0.9174 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 31 Oct 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Panacea Biotec Limited
- NSE symbol
- PANACEABIO
- BSE code
- 531349
- ISIN
- INE922B01023
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jan 1996 on BSE, Apr 1996 on NSE
- Face value
- ₹1
- CIN
- L33117PB1984PLC022350
- Corporate identity number, the registrar of companies' code for it